Therapeutic Solutions International (TSOI) 10-K2021 FY Annual report

Filed: 31 Mar 22, 4:44pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: aand, acute, ADCC, adipose, adjunct, agonist, alia, Amazon, Amelioration, Amgen, Anoka, antidepressant, antigen, aorta, AortaCell, aortic, apercentage, apoptotic, assigned, banking, Big, Bioheart, bioleonhardt, biomarker, bispecific, blind, bone, borrowing, broad, Brother, campaign, Carroll, Case, CerebraCell, challenging, chemotactic, chimeric, chloride, chorionic, Christopher, CODP, Conjugation, COPD, core, CRISPR, CRO, Crowdfund, crowdfunding, dealt, depth, desired, destruction, differentiate, Diploma, dopamine, economy, edited, elongation, entrepreneurship, epithelial, Erie, Ernst, European, EUSTM, evoke, exogenously, expertise, extracellular, eye, EyeCell, feeding, Fogarty, Fortune, fused, fusing, fusion, Genelux, genetically, Geron, GITR, gonadotropin, graft, homeostatic, honorary, hormonal, host, house, Howard, hybrid, hypoxia, ICU, ID, immunosuppressive, implantable, Imprinted, incubator, Inline, Instance, intra, intravenously, iPSC, ivermectin, IVIG, Johnson, keratinocyte, Kite, Lake, land, leader, leakage, led, Leonhardt, Linkbase, lithium, LP, magnetic, mammalian, marrow, math, McKinsey, media, medtech, Melacine, Miami, Minev, Mizer, monoclonal, monocyte, Monotherapy, Motif, multiyear, naltrexone, neoplasia, network, neuropathy, neutrophil, nonrefundable, NorCal, Northern, notice, nuclease, oncolytic, opened, Parkinson, pending, perspective, pivotal, placebo, placenta, portfolio, possessing, preparatory, presence, programmable, prominent, protein, pulmonary, pulsed, pump, Ramsey, rebalancing, receptor, recipient, replicate, respiratory, reuptake, Reznik, Rohnert, Rosenberg, salt, saving, scar, Schema, serial, serotonin, SITC, social, sparing, spin, spokesperson, Startup, stent, Steven, stockto, syndrome, TALENT, taught, Taxonomy, team, telomere, Textbook, Thomson, thymoquionone, TM, toll, Trademark, transcranial, trap, trastuzumab, Trauma, UCLA, UCSD, undergraduate, vasculature, venture, Venvalo, virotherapy, wholly, XBRL, Young

Removed: air, apnea, assay, autoimmunity, bioavailability, Biochemistry, Centre, Chemistry, cleared, close, commercialized, consent, cum, deepened, dissolved, droplet, emulsification, extensively, hard, headed, Inaugural, laude, LLP, longer, Lougborough, Mahant, Medicinal, MediLite, Menlo, Milan, Milner, minimum, oxidation, regulated, Salford, SandBox, solubility, Squar, stability, Stanford, strategist, summa, transplanted, UK, Vijay

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

TSOI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

SARBANES-OXLEY SECTION 906 CERTIFICATION

In connection with the Annual Report on Form 10-K of Therapeutic Solutions International, Inc. (the “Company”) for the year ending December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Timothy G. Dixon, Chief Executive Officer, President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 29, 2022

By:	/s/ Timothy G. Dixon
	Timothy G. Dixon
	Chief Executive Officer and President
	(Principal Executive Officer)
	Chief Financial Officer
	(Principal Financial Officer)